Placebo News and Research

RSS

XenoPort initiates XP23829 Phase 1 study in healthy adults

XenoPort, Inc. announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.

24 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Once-daily Gralise significantly reduces pain intensity in PHN patients

Depomed, Inc. today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN).

23 Jul 2012

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012

Oral immunotherapy hope for egg allergy in children

Oral immunotherapy for the treatment of egg allergy results in desensitization with long-lasting results in three-quarters of children, show study findings.

23 Jul 2012

Herbal therapy no alternative in HCV infection

The commonly used herbal remedy, silymarin, offers no benefit to patients with treatment-resistant hepatitis C virus infection, a study shows.

23 Jul 2012

Linagliptin safe and effective for long-term management of type 2 diabetes

An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either on its own or in combination with other selected oral anti-diabetic medication.

23 Jul 2012

Egg allergy treatment for children: an interview with Dr Robert Wood

The tendency to get allergies is a fairly general one, which is mostly inherited – it tends to run in families. There are several foods that are most common for children to become allergic to: milk, egg and peanuts in most countries are the most common food allergies.

23 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.

21 Jul 2012

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

21 Jul 2012

Phosphate binders may cause unexpected harm to blood vessels in patients with CKD

Drugs commonly prescribed to patients with chronic kidney disease (CKD) may not be as strongly effective as once thought, and may cause unexpected harm to blood vessels, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

20 Jul 2012

Knee surgery blood loss reduced with single tranexamic acid dose

A single intraoperative dose of tranexamic acid is effective at reducing blood loss in patients undergoing minimally invasive total knee arthroplasty, research suggests.

20 Jul 2012

Unexplained fatigue in women: start iron supplements

Iron deficiency may be underdiagnosed in women of child-bearing age who report considerable fatigue, say researchers whose randomized controlled trial results show a significant reduction in fatigue after women took iron supplements.

20 Jul 2012

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

CPAP effectively reduces symptoms and improves QOL in sleepy patients with milder OSA

Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according to a new study.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Iron deficiency in women ‘may be under-recognized’

Iron deficiency may be an under-recognized cause of fatigue in women, say investigators who report that iron supplementation reduced symptoms of fatigue in women who were not anemic but had low ferritin levels.

19 Jul 2012

New hope for children with egg allergy

Doctors currently have only one recommendation for people allergic to eggs: avoid eggs completely. But researchers at the University of North Carolina School of Medicine recently found promise in doing just the opposite. Eating small amounts of egg every day for many months lowered the threshold for allergic reactions in 75 percent of egg-allergic children; 28 percent were able to incorporate egg into their regular diets after two years on the treatment.

19 Jul 2012